Biology of Liver Metastases

  • Russell S. Berman
  • Charles A. PorteraJr.
  • Lee M. Ellis
Part of the Cancer Treatment and Research book series (CTAR, volume 109)


Metastasis is the major cause of death from cancer. By the time many cancers are diagnosed, metastasis has already occurred and the presence of multiple metastases makes complete eradication by surgery, radiation, chemotherapy, or biotherapy nearly impossible. As with other cancers, current therapies for distant metastatic disease have had minimal impact on outcome. Modifications of current treatment regimens are unlikely to significantly impact the natural history of liver metastases. Therefore, a better understanding of the biology of metastasis and the molecular events leading to the metastatic phenotype is essential if new and innovative anti-neoplastic therapeutic approaches are to be developed. This review will highlight the molecular and biologic alterations that occur in tumors that lead to the development of liver metastasis. Although numerous tumors have the potential to metastasize to the liver, metastases from colon cancer will be used as a paradigm for liver metastasis in this review.


Vascular Endothelial Growth Factor Colon Cancer Liver Metastasis Hepatocyte Growth Factor Colorectal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50:6130–6138.PubMedGoogle Scholar
  2. 2.
    Fidler I, Radinsky R. Genetic control of cancer metastasis (editorial). J Natl Cancer Inst 1990; 82:166–168.PubMedCrossRefGoogle Scholar
  3. 3.
    Kerbel R. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects. Adv Cancer Res 1990; 55:87–132.CrossRefGoogle Scholar
  4. 4.
    Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995; 87:1588–1592.PubMedCrossRefGoogle Scholar
  5. 5.
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571–573.CrossRefGoogle Scholar
  6. 6.
    Ewing J. Neoplastic Diseases. Philadelphia: WB Saunders, 1928.Google Scholar
  7. 7.
    Sugarbaker E. Patterns of metastasis in human malignancies. Cancer Biolov Review 1981: 2:235–278.Google Scholar
  8. 8.
    Hart I. “Seed and soil” revisited: Mechanisms of site specific metastasis to specific secondary sites. Cancer Metastasis Rev 1982; 1:5–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Tarin D, Price J, et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44.Google Scholar
  10. 10.
    Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? - G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986; 46:467–473.PubMedGoogle Scholar
  11. 11.
    Fidler IJ, Ellis LM. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell 1994: 79:185–188.PubMedCrossRefGoogle Scholar
  12. 12.
    Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964–3968.PubMedGoogle Scholar
  13. 13.
    Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95:1789–1797.PubMedCrossRefGoogle Scholar
  14. 14.
    Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and VEGF expression as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541–546.PubMedCrossRefGoogle Scholar
  15. 15.
    Tong W-M, Ellinger A, Sheinin Y, Cross HS. Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. British Journal of Cancer 1998; 77:1792–1798.PubMedCrossRefGoogle Scholar
  16. 16.
    Guo Y-S, Narayan S, Chandrasekhar Y, Singh P. Characterization of insulin-like growth factor I receptors in human colon cancers. Gastroenterology 1992; 102:1101–1108.PubMedGoogle Scholar
  17. 17.
    Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Ann Rev Biochem 1988; 57:443.PubMedCrossRefGoogle Scholar
  18. 18.
    Markowitz SD, Molkentin K, Gerbic C, al e. Growth stimulation by coexpression of transforming growth factor-a and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J Clin Invest 1990; 86:356.PubMedCrossRefGoogle Scholar
  19. 19.
    Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clinical Cancer Research 1995; 1:19–31.PubMedGoogle Scholar
  20. 20.
    Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequental treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clinical Cancer Research 1999; 5:909–916.PubMedGoogle Scholar
  21. 21.
    Singh P, Rubin N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993; 105:1218–1237.PubMedGoogle Scholar
  22. 22.
    Rosenfeld RG. Biological functions of IGF receptors. In: Frisch H, Thorner MO, eds. Hormonal regulation of growth. New York: Raven, 1989:113–126.Google Scholar
  23. 23.
    Rechler MM, Nissley SP. The nature and regulation of the receptors for insulin-like growth factors. Ann Rev Physiol 1985; 47:425.CrossRefGoogle Scholar
  24. 24.
    Michell NP, Dent S, Langman MJS, Eggo MC. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell nroliferation. Growth Factors 1996; 14:269–277.CrossRefGoogle Scholar
  25. 25.
    Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulinlike growth factor-I. Cancer Research 1998; 58:4008–4014.PubMedGoogle Scholar
  26. 26.
    Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specifiic metastasis. Cancer Metastasis Rev 1993; 12:345–361.PubMedCrossRefGoogle Scholar
  27. 27.
    Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995; 19:226–234.PubMedCrossRefGoogle Scholar
  28. 28.
    Gabbert H. Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev 1985; 4:293–309.PubMedCrossRefGoogle Scholar
  29. 29.
    Liotta LA. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986; 46:1–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Martin M, Pujuguet P, Martin F. Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Path Res Pract 1996; 192:712–717.PubMedCrossRefGoogle Scholar
  31. 31.
    Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14:455–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Matrisian LM, Wright J, Newell K, Witty JP. Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 1994: 24:152–61.PubMedGoogle Scholar
  33. 33.
    Levy Cioce V, Sobel ME, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51:439–44.PubMedGoogle Scholar
  34. 34.
    Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1990; 82:1890–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44:139–266.PubMedCrossRefGoogle Scholar
  36. 36.
    deBruin PA, Griffioen G, Verspaget HW, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988; 48:4520–4.Google Scholar
  37. 37.
    Csoka TB, Frost GI, Stern R. Hyaluronidases in tissue invasion. Invasion Metastasis 1997; 17:297–311.PubMedGoogle Scholar
  38. 38.
    Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T, Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 1997; 82:632–638.CrossRefGoogle Scholar
  39. 39.
    Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Research 1995; 55:3629–3633.PubMedGoogle Scholar
  40. 40.
    Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Research’ 1994; 55:4726–4728.Google Scholar
  41. 41.
    Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lunch cancer. J Clin Oncol 1998; 16:2150–6.PubMedGoogle Scholar
  42. 42.
    Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994: 107:1183–8.PubMedGoogle Scholar
  45. 45.
    Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 1997; 94:3336–3340.PubMedCrossRefGoogle Scholar
  46. 46.
    Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9:541–73.PubMedCrossRefGoogle Scholar
  47. 47.
    Koretz K, Schlag P, Boumsell L, Moller P. Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 1991; 138:741–50.PubMedGoogle Scholar
  48. 48.
    Hemler ME, Crouse C, Sonnenberg A. Association of the VLA alpha 6 subunit with a novel protein. A possible alternative to the common VLA beta 1 subunit on certain cell lines. J Biol Chem 1989; 264:6529–35.PubMedGoogle Scholar
  49. 49.
    Pignatelli M, Smith ME, Bodmer WF. Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br J Cancer 1990; 61:636–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995; 55:4132–9.PubMedGoogle Scholar
  51. 51.
    Kikkawa Y, Umeda M, Miyazaki K. Marked stimulation of cell adhesion and motility by ladsin, a laminin-like scatter factor. J Biochem (Tokyo) 1994; 116:862–9.Google Scholar
  52. 52.
    Rabinovitz I, Nagle RB, Cress AE. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 1995; 13:481–91.PubMedCrossRefGoogle Scholar
  53. 53.
    Raftopoulos I, Davaris P, Karatzas G, Karayannacos P, Kouraklis G. Level of a-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential and survival. Journal of Surgical Oncology 1998; 68:92–99.PubMedCrossRefGoogle Scholar
  54. 54.
    Gofuku J, Shiozaki H, Tsujinaka T, et al. Expression of E-cadherin and a-catenin in patients with colorectal carcinoma. Am J Clin Pathol 1999; 111:29–37.PubMedGoogle Scholar
  55. 55.
    Hiscox S, Jiang WG. Expression of E-Caderin, a, b and y-catenin in human colorectal cancer. Anticancer Research 1997; 17:1349–1354.PubMedGoogle Scholar
  56. 56.
    Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57:327–34.PubMedCrossRefGoogle Scholar
  57. 57.
    Jessup JM, Petrick AT, Toth CA, et al. Carcinoembryonic antigen: enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 1993; 67:464–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Barbera-Guillem E, Smith I, Weiss L. Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery. Int J Cancer 1992: 52:974–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. The Lancet 1993; 341:725–726.CrossRefGoogle Scholar
  60. 60.
    Coulombe J, Pelletier G. Gangliosides and organ-specific metastatic colonization. Int J Cancer 1993; 53:104–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Irimura T, Nakamori S, Matsushita Y, et al. Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-Lex antigens. Seminars in Cancer Biology 1993; 4:319–324.PubMedGoogle Scholar
  62. 62.
    Morris VL, Schmidt EE, MacDonald IC, Groom AC, Chambers AF. Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Invasion Metastasis 1997; 17.Google Scholar
  63. 63.
    Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. Journal of Biological Chemistry 1994; 269:1425–1431.PubMedGoogle Scholar
  64. 64.
    To CTT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and Met receptor in human cancers (review). Oncology Reports 1998; 5:1013–1024.PubMedGoogle Scholar
  65. 65.
    Hiscox SE, Hallett MB, Puntis MCA, Nakamura T, Jiang WG. Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers. Cancer Investigation 1997; 15:513–521.PubMedCrossRefGoogle Scholar
  66. 66.
    Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 1997; 27:378–383.PubMedCrossRefGoogle Scholar
  67. 67.
    Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clinical Cancer Research 1995; 1:147–154.PubMedGoogle Scholar
  68. 68.
    Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to TGFb1 with tumor progression. Cell Growth Differ 1994; 5:267–275.PubMedGoogle Scholar
  69. 69.
    Huang F, Hsu S, Yan Z, Winawer S, Friedman E. The capacity for growth stimulation by TGFbI seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. Oncogene 1994; 9: 3701–3706.PubMedGoogle Scholar
  70. 70.
    Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor b 11. Cancer Epidemiology Biomarkers & Prevention 1998; 7:497–504.Google Scholar
  71. 71.
    Reed, J.C. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11:68–75.PubMedCrossRefGoogle Scholar
  72. 72.
    Hetts WH. Apoptosis and its role in disease. JAMA 1998; 279:300–307.PubMedCrossRefGoogle Scholar
  73. 73.
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Research 1995; 55:1811–1816.PubMedGoogle Scholar
  76. 76.
    Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Research 1996; 56:2422–2427.PubMedGoogle Scholar
  77. 77.
    Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clinical Cancer Research 1998; 4:1071–1074.PubMedGoogle Scholar
  78. 78.
    Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Letters 1997; 115:185–193.PubMedCrossRefGoogle Scholar
  79. 79.
    Takaoka A, Adachi M, Okuda H, et al. Anti-cell death activity promotes pulmonary metastatis of melanoma cells. Ocogene 1997; 14:2971–7.CrossRefGoogle Scholar
  80. 80.
    Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal-deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling. Int J Cancer 1996; 65:173–177.PubMedCrossRefGoogle Scholar
  81. 81.
    Termuhlen PM, Berman RS, Ellis LM, et al. Evidence for increased apoptosis in metastatic human colonic adenocarcinomas. American Journal of Pathology 1999.Google Scholar
  82. 82.
    Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124:619–26.PubMedCrossRefGoogle Scholar
  83. 83.
    Bates RC, Buret A, van Helden DF, Horton MA, Burns GF. Apoptosis induced by inhibition of intercellular contact. Journal of Cell Biology 1994; 125:403–415.PubMedCrossRefGoogle Scholar
  84. 84.
    Berman RS, Sweeney B, McConkey DJ. Metastatic colorectal cancer cells are resistant to anoikis, inducing Akt phosphorylation. Proceedings of 90th Annual Meeting of the American Association for Cancer Research 1999; 40:326 (A2162).Google Scholar
  85. 85.
    Tannapfel A, Katalinic A, Kockerling F, Wittekind C. The prediction of lymph node metastases in colorectal cancer by expression of the nucleoside diphosphate kinase/nm23-H1 and histopathological variables. American Journal of Gastroenterology 1997; 92:1182.PubMedGoogle Scholar
  86. 86.
    Yamaguchi A, al e. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. British Journal of Cancer 1993; 68:1020–4.PubMedCrossRefGoogle Scholar
  87. 87.
    Takaoka A, Hinoda Y, Satoh S, et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene 1998; 16:1443–1453.PubMedCrossRefGoogle Scholar
  88. 88.
    Cajot JF, Sordat I, Silvestre T, Sordat B. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Research 1997; 57:2593–2597.PubMedGoogle Scholar
  89. 89.
    Mori M, Mimori K, Shiraishi T, et al. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clinical Cancer Research 1998; 4:1507–1510.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Russell S. Berman
    • 1
  • Charles A. PorteraJr.
    • 1
  • Lee M. Ellis
    • 1
  1. 1.The University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations